(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

HHS Secretary Robert F. Kennedy Jr. places anti-vaxxers in control of U.S. vaccine policy, slandering an actual expert along ...

AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a ...

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...

Biogen has emerged as a potential front-runner at the Cannes Lions International Festival of Creativity, snagging four spots ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Shares of pharmaceutical company Merck (NYSE: MRK) were recently down about 40% over the past year, partly due to concerns ...

The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ...

Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a ...

Three of the health secretary’s picks to replace fired members of an influential panel that sets U.S. vaccine policies have ...

Protein deficiency is rare in the United States, but some people are at risk for it. Learn the symptoms of protein deficiency ...